Autopsy report · NCT01734057

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

“No eligible patient was enrolled.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Shandong University

Sponsor type

University, hospital or other

Conditions

Purpura; Idiopathic Thrombocytopenic Purpura

Interventions

recombinant human thrombopoietin (rhTPO); rituximab; Dexamethasone

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
  “No eligible patients were enrolled.” (97% match in meaning)
• Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
  “no patient enrolled.” (94% match in meaning)
• Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
  “No patients were enrolled.” (93% match in meaning)
• Energy Expenditure and Gastric Bypass Surgery
  “no patients enrolled.” (92% match in meaning)
• Remote Ischemic Conditioning in Traumatic Brain Injury
  “No eligible participants were enrolled.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.